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Approximately 20,000 cases of bacterial meningitis occur in children per year in
the United States (1). Depending on the etiology, up to 3070 of these children die
and half experience severe sequelae (2) . Paradoxically, morbidity and mortality have
not changed over 30 years despite the introduction ofand continued improvement
in bactericidal antibiotics (1, 3) and it isnow recognized that breakthroughs in limi-
tation of tissue damage in meningitis will not come from greater antibiotic-induced
killing (4) . Recently, evidence has accumulated that adjuncts to antibiotic therapy
that reduce inflammation can achieve reduced mortality (5-9) . Since alarge inflam-
matory mass is associated with a poor outcome of disease (10), it is possible that
some of the benefits of these agents derive from their ability to decrease accumula-
tion of leukocytes in cerebrospinal fluid (CSF) . t
The contribution ofleukocytes to neuronal and endothelial injury during menin-
gitis is unresolved . Studies using cyclophosphamide to induce neutropenia, have
provided evidence both against (11, 12)andfor (11, 13-15) leukocyte-mediated damage,
but side effects of cyclophosphamide limit their reliability. We have re-examined the
role of leukocytes by using mAbs against the CD18 family of adhesion-promoting
receptors on leukocytes (reviewed in reference 16) to block their movement. The
CD18 complex is composed of three members, CD11a/CD18 (LFA-1), CD11b/CD18
(CR3 or Macl), and CDllc/CD18 (p150,95) (17, 18). Expression offunctional CD18
molecules appears essential for migration of inflammatory cells since patients with
a genetic defect in CD18 (LAD, reference 18) fail to mobilize leukocytes to sites of
inflammation, and infusion of anti-CD18 mAbs into animals blocks emigration of
leukocytes into peripheral sites in response to noninfectiousstimuli (19, 20) . In vitro
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studies show that CD18 molecules are necessary for the initial binding of leukocytes
to endothelium (21, 22).
Here we show that intravenous infusion of antibodies against CD18 into rabbits
inhibits the recruitment of leukocytes across the blood brain barrier in response to
acute inflammatory stimuli of bacterial origin . Antibody-induced limitation ofleu-
kocyte emigration into the CSF is associated with decreased blood brain barrier in-
jury and cerebral edema and prevention of mortality.
Materials and Methods
Bacterial Strains and Products.
￿
Streptococcuspneumoniae strain SIII, type III, and an unencap-
sulated strain R6 were grown in semisynthetic medium (23). Haemophilus influenzae strain Eagan,
Type B, or Neisseria meningitidis, type b, were grown in brain heart infusion broth supplemented
with 517o Fildes enrichmentmedia(BBL Microbiology Systems, Cockeysville, MD) (23). Pneu-
mococcal cell wall (preparation B, reference 24) or LPS (Re; List Biological, Campbell, CA)
were suspended in pyrogen-free saline by sonication before injection into the rabbits.
mAb IB4 (IgG2A) directed against CD18 and mAb OKMI (IgG2B) directed against CD11b
were as described (17). mAb 60.3 (IgG2A) against CD18 was a generous gift of Dr. John
Harlan (University of Washington, Seattle, WA) (22). Antibodies were administered either
as ascites fluids or as purified Ig with equivalent results.
Induction ofMeningitis.
￿
2-kg female New Zealand white rabbits (Hare Marland, Nutley,
NJ) were anesthetized with acombination ofKetamine (Parke-Davis, Morris Plains, NJ)/Xyla-
zine (Miles Laboratories, Shawnee, KS) at a dose of 35 and 2 .5 mg/kg, respectively, by the
intramuscular route and a dental acrylic helmet was affixed to the calvarium (23). 24 h later
the rabbits were reanesthetized with subcutaneous ethyl carbamate (Urethane, 1 .75 g/kg;
Aldrich Chemical Co., Milwaukee, WI) followed by pentobarbital (Nembutal, 15 mg/kg; Ab-
bott Laboratories, Abbott Park, IL) intravenously and then placed on stereotaxic frames.
A Quincke spinal needle (24 gauge by 3.5 in; Becton Dickinson & Co., Parsippany, NJ) was
introduced into the cisterna magna with a geared electrode introducer. After withdrawal of
300 p.l ofCSF, the inoculum (200 td) was introduced followed by repeated sampling of CSF
(200 I.1) at 2-h intervals.
Study Design.
￿
Animals were studied in groups of eight; half of the rabbits in each group
were treated with mAb IB4 (1 mg protein/kg) administered as an intravenous bolus dose.
Acute Inflammation.
￿
Rabbits were challenged intracisternally (i.c.) with one of the following:
10' CFU of washed living S. pneumoniae, H. in fluenzae, or N. meningitidis, 50 Wg of pneumo-
coccal cell wall, or 25 ng of LPS. mAb was administered intravenously 40 min before in-
tracisternal challenge. CSF samples were tested for leukocyte density, protein concentration,
histology of leukocyte infiltrate, and bacterial density (23).
To study the effect of alterations in the regimen of therapy with the antibody on the course
of acute meningeal inflammation, a highly reproducible inflammation was induced by chal-
lenge with 10$ CFU equivalents of heat-killed pneumococci. In one set of experiments,
rabbits were rendered complement deficient by treatment with Cobra venom factor (Naja
haja ; Cordis Laboratories, Miami, FL) 75 U/kg s.c. at 24, 18, and 12 h and intravenously
0.5 h before intracisternal challenge (25). In a second set ofexperiments, blood brain barrier
permeability was quantitated by following accumulation in CSF of intravenously infused
'251-human serum albumin (HSA) (14). HSA (Armour Pharmaceuticals, Kankakee, IL) was
iodinated by the iodogen procedure (26) and 100 pCi/kg was infused at 5 h after pneumo-
coccal challenge; control animals received saline intracisternally. Permeability was calculated
as cpm CSF/cpm blood x 100 at 2 h after infusion of 1211-HSA.
Established Meningitis.
￿
In a second set of experiments, 10' cell equivalents of heat-killed
pneumococci were administered intracisternally at 0, 3, 6, 24, 27, and 30 h and the course
of CSF inflammation, survival, and brain edema (dry versus wet weight of cerebral hemi-
spheres and cerebellumexcised immediately at death (61) were assessed. mAb IB4 was given
intravenously at 0 h (1 mg/kg) and 24 h (0.1 mg/kg) to half of the rabbits.
The impact ofthe mAb on the outcome of therapy of active pneumococcal meningitis wastested inanimalsreceiving intravenous ampicillin (30 mg/kg) 14hintoestablishedinfection.
mAb IB4 was given intravenously simultaneously with the antibiotic (1 mg/kg) and 6, 18,
and 24 h later (0.1 mg/kg).
Results
ReductionofAcuteMeningealInfammation by mAbIB4.
￿
Animals receivingmAbIB4
demonstrated a dramatic reduction in CSF leukocyte density following challenge
with living bacteria, endotoxin, or cell wall (p < 0.001 by analysis ofvariance; Fig.
1). Inthefirst few hours, leukocytes were >90% polymorphonuclear, but thereafter,
mononuclear cells also appeared in control animals. mAb IB4 blocked influx
throughoutthetime course studied(Table I), suggesting itwaseffectiveininhibiting
migration of both major classes ofleukocytes. The few leukocytes that did appear
in the subarachnoid space despite administration ofmAb were 90% mononuclear.
mAb IB4 appeared to act by blocking migration ofcirculatingcells into CSF, not
by removing leukocytes from the circulation. Aperipheral leukocytosis developed
in control animals receiving intravenous mAb IB4, consistent with the release of
leukocytes from a marginated pool. Before mAb administration, leukocyte density
was 8,960 t 810 cells/,,1; 2, 4, and 7 h later, values increased to 33,720 t 1,324;
25,200 t 2,203; and 98,490 t 3,901, respectively. The circulating leukocytes re-
mained viable as assessed by exclusion of trypan blue.
Effect of Variation in Therapeutic Regimen.
￿
After standard challenge ofheat-killed
pneumococci (Table I), blockade ofleukocytosis wasequally effectiveat dosesofmAb
of 1.0 and 0.1 mg/kg administered 30-60 min before the bacterial challenge. The
mAb remained effective even if given only 10 min before bacterial challenge but
not if given 24 h before the bacterial challenge. Thus, blockade ofleukocyte move-
ment by the mAbwas transient. Intracisternal rather than intravenous administra-
tion ofmAb did not protect against CSF leukocytosis, suggesting that the antibody
must interfere with leukocyte adherence on the systemic, not the cisternal, side of
the blood brain barrier in order to be effective.
Sincethereisadelay inleukocyte accumulation in animals decomplemented with
cobra venom factor (Table I; reference 25), complement components appear to par-
ticipate in the early phase ofrecruitment ofleukocytes into cerebrospinal fluid (27).
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FIGURE 1.
￿
The effect of mAb IB4 on leu-
kocytosis in cerebrospinal fluid in response
to intracisternal challenge with bacteria or
purified bacterial products. The density of
leukocytes in cerebrospinal fluid was mea-
sured in control rabbits (closed symbols) or
rabbits pretreated with mAb IB4 (open
symbols) after challengewith livingbacteria
(left) or purified bacterial components
(right). (Left) Pneumoeoccus (circle), H.
influenzae(triangle), meningococcus (square).
(Right) Cell wall (circle), endotoxin (triangle).962 REDUCTION OF CSF INFLAMMATION BY ANTILEUKOCYTE ANTIBODIES
TABLE I
Effect of Variation in Regimen of Treatment with mAb on the Development of Leukocytosis in CSF
Animals received mAb IB4 30-60 min before intracisternal (i.c.) challenge with 8 x 107 heat-killed unen-
capsulated pneumococci R6 suspended in pyrogen-free saline (23). Values for groups designated bacteria
alone and bacteria plus mAb IB4 1 mg/kg i .v. are the mean t SD of leukocyte densities from six
animals/group. All other values are the mean t range of leukocyte densities from pairs of animals.
' Significantly different from bacteria alone.
1 Significantly different from bacteria + CoVF. h < 0.001 by one-way analysis of variance.
However, decomplemented animals eventually do show a dramatic leukocytosis that
is presumed to result from the generation of metabolites of arachidonic acid (25).
mAbIB4strongly blocked both the early complement-dependent phaseof chemotaxis
ofleukocytes in normal animalsand the late complement-independent phaseofrecruit-
ment in complement-depleted animals (Table I).
The specificity of the effects of mAb IB4 is indicated by the observation that an
additional anti-CD18 mAb, 60.3, also blocked meningeal inflammation (<22 t 13
cells/lA at 6hin mAb60.3-treated animals vs. 2,800 t 607cells/I.1 in control animals;
p < 0.001 by analysis of variance). In contrast, mAb OKMI directed against
CD11b/CD18 did not interfere with the development of leukocytosis in CSF (mean
leukocyte density 1,453 ± 265 cells/,.1 at 6 h). Though raised against humanleuko-
cytes, mAbs 1134, 60.3, and OKMI each reactedstrongly with rabbit leukocytes (data
not shown).
Protective Activity ofIB4 Against BloodBrain Barrier Injury, Cerebral Edema, andMor-
tality. Animals pretreated with intravenous mAb IB4 showed a substantial decrease
in blood brain barrierinjury as measured by CSF protein concentration (Table II).
This finding was further substantiated by measurements of the penetration of t2'I-
HSA from blood into CSF (saline i.c. : 1.8%; pneumococcus i.c. : 3.9%; pneumococcus
i.c. + mAb 1134 iv. : 1.5%;p< 0.01). Foras yet unknown reasons, animals receiving
mAb alone showed a small but significant elevation in CSF protein concentration.
The inflammatory response in meningitis is strongly enhanced by treatmentwith
antibiotics, presumably becausethe killed bacteria disintegrate into numerous frag-
ments, each of which serves as anew focus for inflammation (7). To test the efficacy
of mAb IB4 in this context, pneumococcal meningitis was treated with ampicillin
so as to achieve >10 times the minimum inhibitory concentration in the CSF
Bacteria (i.c.)
Treatment
mAb Other
Mean CSF
4 h
leukocyte density
6 h
(cells/ul)
11 h
- - - 34 t 16 38 ± 14 47 t 26
- 1 mg/kg i.v . - 21 t 10 45 1 30
+ - - 659 1 231 2,532 ± 362
+ 1 mg/kg i.v. - 109 1 24` 168 1 43'
+ 0.1 mg/kg i.v . - 56 t 34' 82 t 29'
+ 1 mg/kg i.c. - 192 ± 31` 1,085 t 371
+ 1 mg/kg i.v. 10 min
before bacteria - 25 t 6* 112 t 4'
+ 1 mg/kg i.v. 24 h
before bacteria - 378 t 58 2,950 t 367
+ - CoVF 120 t 12 300 t 40 2,780 t 930
+ 1 mg/kg CoVF 131 t 33 306 f 15 613 f 2461Treatment (n)
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TABLE II
Elect of Treatment with mAh IB4 on CSF Protein Concentrati
(mg1100 ml) 4 h After Challenge with Inflammatory Bacteria
Median CSF leukocyte
density (cells/ul)
Values are the mean t range of determinations made on pairs of rabbits
challenged intracistemally with high doses ofbacterial components, either in-
tact unencapsulated pneumococcus R6 or purified cell wall (50 Rg) or endotoxin
(25 ng). 1 mg/kg of mAb IB4 was administered intravenously 30 min before
challenge. Protein determinations were made using the BCA protein assay test
kit (Pierce Chemical Co., Rockford, IL).
" Significantly different from control (no stimulus/no mAb) and from + mAb
paired value at p < 0.01 by two-way analysis of variance and Dunnett control
group comparison test. All + mAh values are statistically equivalent to con-
trol (no stimulus/no mAb).
Ampicillin-induced bacterial lysis caused the expected rapid increase in leukocyte
density over that seen in a third group of animals which received no drug (Table
III). This ampicillin-induced burst ofleukocytosis waspreventedbyintravenous (but
not intracisternal) mAb IB4 (Tables III and IV).
The concentration of ampicillin in the CSF of infected animals was lowered by
treatmentwith mAb IB4(Table IV). This result was predictable in view ofthepro-
tection from blood brain barrier permeability afforded by the antibody (Table II).
icillin were above the minimum inhibitory concentra-
tion in all animals, and killing ofbacteria in antibody-treated animals was equiva-
lent (16 > 0.1) to that in untreated animals (Tables III and IV).
Upon clearance of a single dose ofampicillin from serum, the residual bacterial
populationresumes growth, and afteraperiod oftime bacteria escape from the CSF
TABLE III
of Treament with mAb IB4 on Burst of Leukocytosis in CSF
Therapy of Pneumococcal Meningitis with Ampicillin
None (4)
Ampicillin (4)
Ampicillin +
mAb 1134 iv (7)
At least four rabbits/group (n) were inoculated with 103-4 CFU/ml of pneumococci strain SIII
and meningitis was established over 14 h. Ampicillin was administered as an intravenous bo-
lus (6 mg/kg) and a burst ofleukocytosis was documented in comparison to untreated controls.
Some animals received mAb IB4 (1 mg/kg) intravenously 30 min before antibiotic. Two-way
analysis of variance shows a significant difference across treatments (p < 0.01), time (p < 0.01),
and a significant interaction (p < 0.05) between the time of onset of leukocytosis and treat-
ment with antibiotic with or without antibody.
963
1,317 2,223 2,523 +1 .2
529 7,051 9,194 -1 .6
224 246 2,142 -1 .0
Stimulus No mAb + mAb
None 50 t 10 128 t 16
8 x 107 Heat-killed pneumococci R6 352 t 12* 111 t 12
108 Cell equivalents of cell wall 300 t 60* 136 t 20
107 Cell equivalents of endotoxin 330 t 36* 113 t 37964
￿
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into the blood. Bacteremia was first detected in animals treated with ampicillin at
37 h afterintracisternal inoculation (Table IV). However, in animals receivingmAb
IB4 plus ampicillin, detection of bacteremia was delayed until 60 h of meningeal
infection. The density ofbacteria in CSFin the two groups was thesame at all times,
i.e., bacterial multiplication in CSFbefore ampicillin and ampicillin-induced killing
in CSF was equivalent in the presence or absence of CSF leukocytosis (Table IV).
Bacterial denisities in blood were not affected by the presence of antibody, as evi-
denced by identical titers in animals challenged with 105 pneumococci intravenously
with and without antibody (data not shown). Thus, mAb IB4 does not affect the
rates of bacterial growth or killing in blood or CSF, but does delay dissemination
of the infection. In an additional meningitis experiment similarto that in Table IV,
only 1 of 4 control animals recovered without sequelae, while all 10 animals treated
with four doses of mAb (12, 18, 24 and 30 h) experienced complete recovery by 5 d
after ampicillin (30 mg/kg at 12 h).
The contribution of leukocytes to brain damage was tested using a protocol in
which pathology was all intracranial (i.e., inflammatory challenge known to remain
in the subarachnoid space [25]). Six intracisternal doses of 10s heat-killed pneu-
mococci resulted in dramatic CSF inflammation (Fig. 2) and between 36 and 40 h
allcontrol animals died. In contrast, animals receiving mAb IB4 at 0 and 24 hwere
protected against the development of CSF inflammation and death (Fig. 2). 72 h
afterintracisternal challenge with alethal dose ofbacteria, rabbitstreated with mAb
IB4 were not only alive but appeared perfectlywell. ThemAb also protected against
the development of brain edema. Brain weight in control animals dying of menin-
gitis was 415.7 t 3.0 g water/100 g dry brain weight versus 394 t 4.2 for mAb-
treated animals (p < 0.01). Brain weight in normal rabbits was 396 t 2.7, a value
not different from mAb-treated groups (p > 0.1).
The effect of mAb IB4on inflammation appeared to be transientsinceleukocytes
became detectable in CSF at 24 h afterthe first dose of antibody (Fig. 2). However,
the leukocyte density again decreased sharply after a second dose of mAb. This re-
sult also suggests that leukocytes have a half-life in CSF of the order of hours. In
a similar fashion, penetration of protein into CSFwas inhibited for>6 h by the first
dose of mAb and increased by 24 h. After the second dose of antibody, protein con-
centrations remained stably high.
FIGURE 2. Prevention of CSF leukocytosis,
influx ofprotein intoCSF, anddeathby mAb1134
following a lethal dose of pneumococci. Eight
rabbits were challenged intracisternally with 108
cell equivalents of heat-killed pneumococci at
0,3,5,24,27, and 30 h. Five rabbitsreceived mAb
1134 intravenously (1 mg/kg at 0 h; 0.1 mg/kg at
24 h) (closedsymbols);threerabbits served as con-
trols(opensymbols). (Left) Mean leukocytedensity
in CSF; (right)mean CSFprotein concentration.
t, allanimalsdied at 36-48h; s, all animalsalive
and well at >60 h.REDUCTION OF CSF INFLAMMATION BY ANTILEUKOCYTE ANTIBODIES
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Discussion
At least two mechanisms are knownby which leukocytes interact with endothelium.
Onemechanism uses theCD18 complexofreceptors on leukocytes (16, 18), and enables
stimulated leukocytes to adhere to unstimulated, naive endothelium. A second mech-
anism depends on the synthesis of novel molecules on the endothelium, such as
endothelial-leukocyte adhesion molecule (ELAM) in response to specific stimuli (LPS,
TNF, or IL-1) (28). Here we show that nearly all migration across the blood brain
barrier is blocked by anti-CD18 antibodies. In our animal model, the endothelium
has ample exposure to bacterial products that engender CD18-independent adhe-
sion in vitro (28-31), yet little or no CD18-independent migration was observed.
It is notknownwhether ELAM can be expressed on endotheliumofthecentralnervous
system.
This study provides clear evidence that leukocytes play a significant role in causing
several types of intracranial pathology that are sufficiently severe so as to induce
death followingchallengewith both live bacteria and inflammatory bacterialsurface
components. Cerebral edemawasabsent in mAb-treated animals, confirming previous
evidence that activated leukocytes contribute to this damage (11, 32). Limitation of
adherence of leukocytes to endothelial cells decreased three additional parameters
of blood brain barrier permeability in meningitis: (a) influx of serum proteins and
1251-HSAinto CSF, (b) penetration of antibiotics from serum into CSF, and (c) onset
of bacteremia resulting from intracisternal bacterial growth.
Neither the course of bacterial growth in blood nor CSF was adversely affected
by mAb-induced functional neutropenia. This was observed previously in
cyclophosphamide-treated neutropenic rabbits (12) and may be explained by the
inefficiency of phagocytosis in liquid spaces (33). The observation that bacteremia
arising from bacterialmultiplication in CSFwas delayed in the absence of CSFleu-
kocytosis suggests leukocytes may be important in spreading infection between cen-
tral and peripheral spaces either as carriers of bacteria or as causative agents of dis-
rupted endothelial integrity.
Studiesof the treatment ofmeningitis with several antiinflammatory agents (steroids
and nonsteroidal) in combination with antibiotics in humans and animal models
have demonstrated an association between inhibition of inflammation in CSF and
improved outcome of disease (5-9). Our studies indicate that at least part of the
mechanism of such beneficial effects arises from limitation of the accumulation of
leukocytes in the subarachnoid space. While antileukocyte mAbs have been under
investigation forthetherapy of autoimmune diseases in humans (34) andfor protec-
tion against ischemia/reperfusion injury in animal models (35, 36), thedeployment
of such mAbs in infectious diseases has not been explored. Our data demonstrate
that there exists an important rationale for their use in this new context.
Summary
We tested if specific inhibition of recruitment ofleukocytes across the blood brain
barrier from the vascular compartment to the cerebrospinal fluid (CSF) space re-
duced tissue damage and improved the outcome of infection in a rabbit model of
experimental meningitis. The CD11/CD18 complex of receptors on leukocytes pro-
motes adhesion of these cells to endothelia, a process required for egress of cells into
the extravascular space. Intravenous injection of the anti-CD18 mAb IB4 effectivelyTUOMANEN ET AL.
￿
967
blocked the development ofleukocytosis in the CSF of animals challenged intracister-
nally with living bacteria, bacterial endotoxin, or bacterial cell wall. This effect was
associatedwith protection from blood brain barrier injury as measured by exclusion
of serum proteins from CSF in mAb-treated animals. The densities of bacteria in
CSF and the degrees of bacterial killing due to ampicillin were not affected by the
antibody. Animals receiving the antibody experienced a delay in the development
ofbacteremia and a significantly reduced inflammatory response during ampicillin-
induced bacterial killing. Therapy with mAb 1134 prevented development of brain
edema and death in animals challenged with lethal doses ofStreptococcus pneumoniae.
These studies indicate that the major mechanism of leukocyte migration across the
blood brain barrier involves the CD11/CD18 receptors and that inflammatory leuko-
cytes recruited by this mechanism are a major cause of blood brain barrier injury
and cerebral edema during meningitis.
We thank A. R. Hill, P Detmers, A. Aderem, Z. Cohn, and A. Tomasz for critical review
of the manuscript. Statistical calculations were performed by Mr. Ping Li, SUNY Health
Sciences Center, Brooklyn, NY.
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